Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer
- Phase 3 study has demonstrated that Induction Chemotherapy prior to ChemoRadiotherapy significantly increased time-to-treatment failure in comparison to standard ChemoRadiotherapy alone -
MADRID, May 30 /PRNewswire/ -- The Spanish Head
and Neck Cancer Cooperative Group (TTCC) announced toda...
BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the results from a Phase I/II combination study in previously untreated patients with head
and neck cancer will...
/C O R R E C T I O N -- Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee/
In the news release, "Update on the SEAS Study" issued on 21 Jul 2008
07:00 GMT, by Prof Terje Pedersen,SEAS Study Principal Investigator & Head
of Steering Committee over PR Newswire, we are advised by a representative
of the organisation that the following information has been added to the
Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
Summary: Genmab Initiates a Phase I/II Study of Zalutumumab in Combination
With Radiotherapy for the Treatment of Advanced Head
and Neck Cancer.
COPENHAGEN, June 24 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN)
announced today it has initiated a Phase I/II study of zalutumumab
CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
LOS ANGELES, June 23 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc.
(OTC: CBIA), is pleased to announce that the South African Medicines
Control Council has granted approval for a Phase II study in 30 cancer
patients evaluating the protective effect of CB1400 on the
gastrointestional tract ...
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Results of Two Major Clinical Studies TAX 323 and TAX 324 Published
BRIDGEWATER, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Sanofi-aventis
announced today that results of two clinical studies demonstrating that
Taxotere(R) (docetaxel) Injection Concentrate, when added to cisplatin and
Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
BRIDGEWATER, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Sanofi-aventis
announced that the U.S. Food and Drug Administration (FDA) has approved
Taxotere(R) (docetaxel) Injection Concentrate in combination with cisplatin
and 5-fluorouracil for induction therapy of locally advanced squamous cell
DAHANCA Initiates Head and Neck Cancer Study With Genmab's HuMax-EGFr
Summary: Genmab announces the initiation of a Phase III study of HuMax-EGFr to treat head
and neck cancer in cooperation with DAHANCA.
COPENHAGEN, Denmark, Sept. 13 /PRNewswire-FirstCall/ -- Genmab A/S
(OMX: GEN) announced today the initiation of a Phase III study of HuMax-
Survival Data Available from Erbitux Study in First-Line Treatment
of Advanced Head and Neck Cancer
NEW YORK--(BUSINESS WIRE)--Apr 4, 2007 - ImClone Systems
Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE:
BMY) announced today that a first line Phase III study of
ERBITUX(R) (Cetuximab) combined with platinum-based chemotherapy
met the primary endpoint of increasing overall surv...
Survival Data Available From Erbitux Study in First-Line Treatment
of Advanced Head and Neck Cancer
-- First large, randomized Phase III study of ERBITUX with
chemotherapy in recurrent and/or metastatic head
and neck cancer
meets primary endpoint of improving overall survival --
NEW YORK, April 04, 2007 /PRNewswire-FirstCall/ -- ImClone
Systems Incorporated and Bristol-Myers Squibb Company annou...
Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of
Erbitux for Colorectal and Head and Neck Cancer Patients
CHICAGO, DARMSTADT, Germany, June 5, 2007 – This
year’s American Society of Clinical Oncology (ASCO) meeting
in Chicago sees a wealth of promising new data presented regarding
Merck KGaA’s targeted cancer therapy Erbitux®
(cetuximab), further demonstrating the consistent effi...
Regular Yoga Practice Is Associated With Mindful Eating
... We hypothesized that mindfulness - a skill learned either directly or indirectly through yoga -could affect eating behavior," said Kristal, associate head
of the Cancer Prevention Program in the Public Health Sciences Division at the Hutchinson Center.
The researchers found that people who ate min...
Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
...ctice, originally named Raleigh Hematology Oncology, CCNC has grown to a physician staff of thirteen medical oncologists, two radiation oncologists, a head
and neck surgical oncologist and a gynecologic oncologist, and offers services in Raleigh, North Raleigh, Cary, Clayton, and Dunn. The practice provi...
Project Zero Delay Accelerates Drug's Path to Clinical Trial
...hat will benefit patients now and in the future, while speeding up the process and making it more cost efficient," said Alan Barge, vice president and head
of Oncology at AstraZeneca. "AZ is always looking to improve our processes and to optimize value along our pipeline. This achievement is a great examp...
Is Your Hair Taking a Break?
...intained, but there is visible thinning over the crown. Dr. McMichael explained that in both male- and female-pattern hair loss, the hair stays on the head
for a shorter time due to a short growth phase, resulting in baby fine hairs that do not reach their full length or diameter.
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
...A recognizes the benefit of Tekturna HCT for the first-line treatment of patients with moderately high blood pressure," said Trevor Mundel, MD, Global head
of Development at Novartis Pharma AG. "Novartis is committed to supporting the research and development of effective treatments for high blood pressur...
UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201
"We are extremely pleased to be launching the Phase 3 clinical trial so rapidly after the close of the Phase 2 trial," said Barry Sherman, M.D., head
of clinical development at South San Francisco-based BiPar Sciences, which is developing BSI-201. BiPar is a wholly owned subsidiary of Paris-based sa...
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
...mumab and placebo treatment groups. No malignancies were
Professor Sandra V. Navarra, M.D., a principal investigator and head
of Rheumatology at the University of Santo Tomas, Manila, The Philippines, said, "Given the limitations of available therapies, there is a great need ...
Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
...esistance in certain cell lines," said Dr. Brad Thompson, President and CEO of Oncolytics. "We are currently using drug combinations against NSCLC and head
and neck cancers in two separate U.S. Phase II studies."
The investigators examined in vitro combination effects of reovirus alone and in combinatio...
CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
...aive) patients with Squamous Cell Carcinoma of the head
and Neck. Early intervention in this disease is s...lar level, brought about by Multikine treatment of head
and neck cancer patients. The CEL-SCI / NIH colla...ples collected from patients with advanced primary head
and Neck cancer (Oral Squamous Cell Carcinoma) dur...
Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet
...cine provides cross-protection against HPV types 31, 33 and 45, the three most common cancer-causing virus types beyond 16 and 18.
Thomas Breuer, head
of Global Clinical R&D and Chief Medical Officer of GSK Biologicals commented: "These excellent study results confirm the efficacy offered by Cer...
Hand Washing with 4% CHG Antiseptic Kills Flu Viruses
...rator test product.
"With any type of influenza outbreak, managing the spread of virus is the biggest concern," said Carolyn Twomey, RN, Global head
of Clinical Services, Molnlycke Health Care. "Influenza viruses usually spread via sneezing and coughing and contaminating one's hand or hands, and th...
CEL-SCI Posts New Corporate Presentation to Website
...nd includes a review of the science underlying Multikine(R), which the Company is preparing to commence a pivotal Phase III trial for the treatment of head
and neck cancer.
CEL-SCI is developing products that empower immune defenses. Its lead product is Multikine(R) which is currently being readied f...
EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
...carnitine and botanicals.
For more information, please visit http://www.lah.de
Contact Lohmann Animal Health:
Dr. Roland Boerner
of Corporate Communications
Lohmann Animal Health GmbH & Co KG
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
...H is a rare, life-threatening disease," said lead investigator Dr. Nazzareno Galie, Associate Professor of Cardiology at the University of Bologna and head
of the Pulmonary Hypertension Centre at the Institute of Cardiology. "The results of this study are encouraging for PAH clinicians and the patients th...
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
... We are excited to continue to move this drug forward through development," said Sanjay Bhanot, M.D., Ph.D., Vice President of Metabolic Disorders and head
of Translational Medicine at Isis Pharmaceuticals.
Isis scientists presented new data demonstrating that antisense reduction of retinal binding ...
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
... the target sites in the lung, which should lead to lower side effects than associated with systemic cyclosporine exposure," stated Prof. Jurgen Behr, head
of the Division of Respiratory Disease at the Ludwig Maximilians University, Klinikum Grosshadern, Munich, Germany.
"The long-term survival rate ...
Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
...ancer metastases in patients with locally advanced head
and neck squamous cell carcinoma. The findings we...Yoo, M.D., chief medical officer and member of the head
and Neck Cancer Multidisciplinary Team at Karmanos...ant professor of medicine and fellow member of the head
and Neck Cancer Multidisciplinary Team, conducted ...
TNFerade(TM) Phase III Data Presented at ASCO
...been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head
and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-...
Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
"There is a clear and urgent need for improved therapies for patients with acute heart failure," said Piotr Ponikowski, M.D., Ph.D, head
of the department of cardiology at the Clinical Military Hospital in Wroclaw, Poland, a principal investigator of the Pre-RELAX-AHF study and presiden...
Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
...y of Clinical Oncology (ASCO).
"Bayer is committed to discovering new cancer-fighting therapies," said Kemal Malik, MD, Chief Medical Officer and head
of Global Development at Bayer HealthCare. "We are encouraged by these Phase I and II data being presented on BAY 73-4506. These data will help furt...
Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
...itor remain on active treatment, now out 5, 9 and 17 months.
Commenting on the data, Principal Investigator Nicholas Vogelzang, MD, Professor and head
of the Genitourinary Cancer Program at the Nevada Cancer Institute, stated, "perifosine demonstrated impressive single agent activity with an overall ...
Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting
For Chipscreen: For HUYA:
Sophie Cao, M.D. Michael Newman, Ph.D.
of Medical Affairs Executive Vice President, Oncology
+86 755 26719670 +1 858 798-8800
+86 138 23171987 mobile ...
CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
...rove infection control and promote appropriate antibiotic stewardship for these high-risk patients," says Sean Harper, M.D., chief medical officer and head
of Global Development at Amgen.
The CDC Foundation is an independent, nonprofit enterprise that forges effective partnerships between CDC and oth...
Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop
...mitment to meeting the needs of patients with C1 deficiency diseases today, and tomorrow," commented Glenn Tillotson, ViroPharma's senior director and head
of Medical Affairs.
The following abstracts from studies supported by Lev Pharmaceuticals, a company acquired by ViroPharma Incorporated in Oct...
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
...ed cerebrospinal fluid pressure such as those with head
injury and increased intracranial pressure. Opioi...s may obscure the clinical course of patients with head
injury due to effects on pupillary response and co...A(TM) should be used with caution in patients with head
injury, intracranial lesions, or other sources of ...
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
...t achieved by a highly efficient nebulizer, such as the customized small droplet generating eFlow electronic nebulizer," stated Dr. Alexander Moeller, head
of the Research Division, Respiratory Medicine at the University Children's Hospital Zurich, Switzerland.
Previous DSCG therapies were only moder...
AlphaVax Announces Promising Results in Melanoma Studies
...g melanoma-specific tumor antigens to reduce melanoma tumor burden in a state-of-the-art murine melanoma model.
Jedd D. Wolchok, M.D., Ph.D., Lab head
and faculty member at MSKCC, is a medical oncologist who specializes in the treatment of melanoma and in whose laboratory the work was conducted. Dr. ...
Tris Pharma Announces Acceptance of Its First Two NDAs
...dosage forms and allows physicians a limitless number of dose options since the dose can be customized through titration," says Dr. Yu-Hsing Tu, Tris' head
of R&D. "This will be particularly valuable as the technology is leveraged in the development of CNS, pain, and other narrow therapeutic window co...
ADVENTRX Announces Results From ANX-514 Bioequivalence Study
...to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head
and neck cancers.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company whose proprietary product candidates...